Michael W. Jann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael W. Jann has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Scott R. Penzak
Department of Pharmacotherapy, University of North Texas System College of Pharmacy (UNTSCP), University of North Texas Health Science Center (UNTHSC), 3500 Camp Bowie Blvd., Fort Worth, TX, 76107, USA
2 shared publications- William Klugh Kennedy
University of Georgia College of Pharmacy, Savannah
2 shared publications Amulya Tatachar
University of North Texas System College of Pharmacy, Fort Worth, Texas
1 shared publicationAnnesha White
University of North Texas System College of Pharmacy, Fort Worth, Texas
1 shared publicationChad M. VanDenBerg
Midwestern University
1 shared publicationEric C. Kutscher
South Dakota State University
1 shared publication
Latest Publications
- Open Access
- 1 January 2020
- Published by SAGE Publications in Indian Journal of Psychological Medicine
- Vol. 42 (1) , 1-3
Do Asians Patients Require Only Half of the Clozapine Dose Prescribed for Caucasians? A Critical Review
- 1 January 2020
- Published by SAGE Publications in Indian Journal of Psychological Medicine
- Vol. 42 (1) , 1-3
Open AccessDo Asians Patients Require Only Half of the Clozapine Dose Prescribed for Caucasians? A Critical Review
- 1 October 2019
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 83 (8) , 1723-1731
An Elective Course in Lesbian, Gay, Bisexual, and Transgender Health and Practice Issues
Objective. To design, implement and assess a lesbian, gay, bisexual, and transgender (LGBT) health and practice elective course for second- and third-year Doctor of Pharmacy (PharmD) students. Methods. The course focused on health promotion, health care barriers, disease prevention, and treatment throughout an LGBT person’s lifespan. The course included topic discussions, reading assignments, various active-learning activities, an objective structured clinical examination (OSCE) with a transgender person, and guest speakers from the LGBT community. Five quizzes were administered during the course that were mapped to specific session learning objectives and course learning outcomes. Students completed an anonymous pre- and post-course survey on the seven course learning outcomes to assess their knowledge and skills regarding the health of LGBT people. Results. Students exhibited significant learning with improvement in the seven course learning outcomes. The two most improved course learning outcomes were the medications used for LGBT people and summarizing health care resources available to LGBT people. The content of student portfolios included general themes of discrimination, health care access problems, advocacy, inclusive pharmacy environments, and desire to be a better practitioner. More than 91% of the students actively engaged the guest speakers from the LGBT community. Student performance on quizzes and in the OSCE activity was excellent. The capstone presentations covered a variety of topics including LGBT in Islam. Conclusion. Students demonstrated knowledge of the unique health care issues among the LGBT community. This elective course provides a framework for other pharmacy programs to incorporate LGBT health topics into the curriculum and to engage with their local LGBT community.
- 1 October 2019
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 83 (8) , 1723-1731
An Elective Course in Lesbian, Gay, Bisexual, and Transgender Health and Practice Issues
Objective. To design, implement and assess a lesbian, gay, bisexual, and transgender (LGBT) health and practice elective course for second- and third-year Doctor of Pharmacy (PharmD) students. Methods. The course focused on health promotion, health care barriers, disease prevention, and treatment throughout an LGBT person’s lifespan. The course included topic discussions, reading assignments, various active-learning activities, an objective structured clinical examination (OSCE) with a transgender person, and guest speakers from the LGBT community. Five quizzes were administered during the course that were mapped to specific session learning objectives and course learning outcomes. Students completed an anonymous pre- and post-course survey on the seven course learning outcomes to assess their knowledge and skills regarding the health of LGBT people. Results. Students exhibited significant learning with improvement in the seven course learning outcomes. The two most improved course learning outcomes were the medications used for LGBT people and summarizing health care resources available to LGBT people. The content of student portfolios included general themes of discrimination, health care access problems, advocacy, inclusive pharmacy environments, and desire to be a better practitioner. More than 91% of the students actively engaged the guest speakers from the LGBT community. Student performance on quizzes and in the OSCE activity was excellent. The capstone presentations covered a variety of topics including LGBT in Islam. Conclusion. Students demonstrated knowledge of the unique health care issues among the LGBT community. This elective course provides a framework for other pharmacy programs to incorporate LGBT health topics into the curriculum and to engage with their local LGBT community.
- 2 June 2018
- Published by Springer Nature in CNS Drugs
- Vol. 32 (6) , 603
Correction to: Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents
1. In Page 244, under General Pharmacokinetic Principles, Column 1—the following sentence should come after reference 21:
- 2 June 2018
- Published by Springer Nature in CNS Drugs
- Vol. 32 (6) , 603
Correction to: Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents
1. In Page 244, under General Pharmacokinetic Principles, Column 1—the following sentence should come after reference 21:
- 22 March 2018
- Published by Springer Nature in CNS Drugs
- Vol. 32 (3) , 241-257
Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents
Schizophrenia is a chronic medical condition with periods of remission and relapses over a patient’s lifetime. Antipsychotic medications represent the mainstay of treatment for this disease. Long-acting injectable (LAI) formulations of antipsychotics are an attractive alternative to their oral counterparts, as they enhance patient adherence. A number of second-generation antipsychotics (SGAs) are available in LAI formulations. These include paliperidone, aripiprazole, olanzapine, and risperidone. This article reviews the most recently developed and approved of these formulations—aripiprazole monohydrate, aripiprazole lauroxil, and paliperidone palmitate. While all were initially available as once-monthly formulations, a paliperidone palmitate 3-monthly injection formulation has been approved and is the first LAI agent to extend the dosing administration beyond the typical monthly time period. In addition, aripiprazole lauroxil every 6-week and 8-week administration preparations have been developed. LAI preparations of the SGAs have all demonstrated superiority over placebo and are comparable to their oral counterparts in terms of safety and tolerability, if injection site reactions are not taken into account. First-generation antipsychotic LAI preparations (e.g., haloperidol decanoate) have recently been compared with SGA LAI agents, and both formulations demonstrated comparable efficacy with the expected adverse events seen with each drug. Despite their availability, barriers to the use of LAIs remain. Education of both patients and clinicians on the use of LAI formulations and the continued development of these agents are important steps in ensuring these medications are available to the patients they would be most likely to benefit.
- 22 March 2018
- Published by Springer Nature in CNS Drugs
- Vol. 32 (3) , 241-257
Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents
Schizophrenia is a chronic medical condition with periods of remission and relapses over a patient’s lifetime. Antipsychotic medications represent the mainstay of treatment for this disease. Long-acting injectable (LAI) formulations of antipsychotics are an attractive alternative to their oral counterparts, as they enhance patient adherence. A number of second-generation antipsychotics (SGAs) are available in LAI formulations. These include paliperidone, aripiprazole, olanzapine, and risperidone. This article reviews the most recently developed and approved of these formulations—aripiprazole monohydrate, aripiprazole lauroxil, and paliperidone palmitate. While all were initially available as once-monthly formulations, a paliperidone palmitate 3-monthly injection formulation has been approved and is the first LAI agent to extend the dosing administration beyond the typical monthly time period. In addition, aripiprazole lauroxil every 6-week and 8-week administration preparations have been developed. LAI preparations of the SGAs have all demonstrated superiority over placebo and are comparable to their oral counterparts in terms of safety and tolerability, if injection site reactions are not taken into account. First-generation antipsychotic LAI preparations (e.g., haloperidol decanoate) have recently been compared with SGA LAI agents, and both formulations demonstrated comparable efficacy with the expected adverse events seen with each drug. Despite their availability, barriers to the use of LAIs remain. Education of both patients and clinicians on the use of LAI formulations and the continued development of these agents are important steps in ensuring these medications are available to the patients they would be most likely to benefit.
- 3 March 2016
- Published by Springer Nature
- p. 579-601
Clinically Significant Interactions with Anesthetic Agents
- 3 March 2016
- Published by Springer Nature
- p. 579-601
Clinically Significant Interactions with Anesthetic Agents
- 3 March 2016
- Published by Springer Nature
- p. 373-394
Anesthetic Drugs Pharmacokinetics and Pharmacodynamics
- 3 March 2016
- Published by Springer Nature
- p. 373-394
Anesthetic Drugs Pharmacokinetics and Pharmacodynamics
- 3 March 2016
- Published by Springer Nature
- p. 351-372
Anti-addiction Agents
- 3 March 2016
- Published by Springer Nature
- p. 329-349
Antidementia Drugs